Geir Øystein Andersen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Geir Øystein Andersen has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Kaspar Broch
Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway
3 shared publications Kjetil Sunde
Division of Emergencies and Critical Care, Oslo University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Norway
3 shared publications- Pavel Hoffmann
Section for Interventional Cardiology, Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway
3 shared publications - Bente Halvorsen
Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
2 shared publications - Camilla Huse
Research Institute of Internal Medicine (T.U., T.B.D., A.M., C.H., P.A., B.H.), Oslo University Hospital Rikshospitalet, Norway
2 shared publications Christofer Lundqvist
Institute of Clinical Medicine, University of Oslo, Norway; Department of Neurology, Akershus University Hospital, Oslo, Norway; Health Services Research Unit, Akershus University Hospital, Oslo, Norway
2 shared publications
Latest Publications
- 1 June 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (6)
Effect of Interleukin-6 Receptor Inhibition by Tocilizumab on Platelet Activation and Markers of Thrombus Formation: A Substudy of the ASSAIL-MI Trial
BACKGROUND: The bidirectional interaction between inflammation and thrombus formation plays an important role in myocardial infarction (MI) with IL (interleukin)-6 as a central mediator. If anti-inflammatory therapy modulates coagulation factors, and platelet activation in patients with MI is not clear. METHODS: We have shown that tocilizumab, a monoclonal antibody targeting IL-6R (IL-6 receptor), improves myocardial salvage index in patients with ST-elevation MI. Herein, we measured levels of soluble markers of platelet activation (P-selectin, sCD40L [soluble CD40 ligand]) and coagulation (TF [tissue factor], TFPI [TF pathway inhibitor], PAI [plasminogen activator inhibitor]-1, and D-dimer) in 136 patients with ST-segment–elevation MI (70 tocilizumab and 66 placebo). Platelet-poor EDTA plasma samples were obtained at admission and after 24 and 168 hours. Temporal changes were related to TnT (troponin T), as well as infarct size and myocardial salvage index, assessed by cardiac magnetic resonance imaging. RESULTS: Our major findings were given as follows: (1) patients had higher sCD40L, P-selectin, TFPI, and D-dimer than 28 healthy controls, and these increased during 1-week follow-up, while TFPI decreased; (2) tocilizumab attenuated P-selectin in patients with short symptom duration at 24 hours in particular in those with high C-reactive protein, and this change correlated positively with indices of myocardial damage; (3) tocilizumab augmented TF at 168 hours, and this change correlated positively with infarct size and negatively with myocardial salvage index; (4) change in D-dimer at 168 hours correlated positively with infarct size and negatively with myocardial salvage index in particular in those with long symptom durations or treated with placebo; tocilizumab attenuated these changes; and (5) the use of heparin attenuated sCD40L levels and increased TFPI levels in admission samples and TF levels after 168 hours. CONCLUSIONS: Our findings support attenuation of platelet activation/coagulation by tocilizumab in patients with ST-segment–elevation MI. The marked rise in TF could be a hereto unrecognized side effects of tocilizumab, which need further investigation.
- 1 June 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (6)
Effect of Interleukin-6 Receptor Inhibition by Tocilizumab on Platelet Activation and Markers of Thrombus Formation: A Substudy of the ASSAIL-MI Trial
BACKGROUND: The bidirectional interaction between inflammation and thrombus formation plays an important role in myocardial infarction (MI) with IL (interleukin)-6 as a central mediator. If anti-inflammatory therapy modulates coagulation factors, and platelet activation in patients with MI is not clear. METHODS: We have shown that tocilizumab, a monoclonal antibody targeting IL-6R (IL-6 receptor), improves myocardial salvage index in patients with ST-elevation MI. Herein, we measured levels of soluble markers of platelet activation (P-selectin, sCD40L [soluble CD40 ligand]) and coagulation (TF [tissue factor], TFPI [TF pathway inhibitor], PAI [plasminogen activator inhibitor]-1, and D-dimer) in 136 patients with ST-segment–elevation MI (70 tocilizumab and 66 placebo). Platelet-poor EDTA plasma samples were obtained at admission and after 24 and 168 hours. Temporal changes were related to TnT (troponin T), as well as infarct size and myocardial salvage index, assessed by cardiac magnetic resonance imaging. RESULTS: Our major findings were given as follows: (1) patients had higher sCD40L, P-selectin, TFPI, and D-dimer than 28 healthy controls, and these increased during 1-week follow-up, while TFPI decreased; (2) tocilizumab attenuated P-selectin in patients with short symptom duration at 24 hours in particular in those with high C-reactive protein, and this change correlated positively with indices of myocardial damage; (3) tocilizumab augmented TF at 168 hours, and this change correlated positively with infarct size and negatively with myocardial salvage index; (4) change in D-dimer at 168 hours correlated positively with infarct size and negatively with myocardial salvage index in particular in those with long symptom durations or treated with placebo; tocilizumab attenuated these changes; and (5) the use of heparin attenuated sCD40L levels and increased TFPI levels in admission samples and TF levels after 168 hours. CONCLUSIONS: Our findings support attenuation of platelet activation/coagulation by tocilizumab in patients with ST-segment–elevation MI. The marked rise in TF could be a hereto unrecognized side effects of tocilizumab, which need further investigation.
- Open Access
Myocardial Tug-of-War Is a Determinant of Left Ventricular Function and Failure
Background: Heart failure with reduced ejection fraction is a leading cause of death worldwide, characterized by impaired left ventricular systolic function. Contractile, structural, and electrophysiological changes underpin this impairment, but how these changes collectively determine ventricular function remains unclear. We hypothesize that their integrated action involves a complex mechanical interplay at the myocardial mesoscale level, intermediate between individual cardiomyocytes and the global left ventricle. Methods: We acquired high-resolution magnetic resonance images of healthy individuals and patients with myocardial infarction, and developed an analytical method to characterize in vivo contraction patterns in millimeter-sized myocardial units (i.e., at the mesoscale). Furthermore, we employed computational models to examine how mesoscale contraction patterns relate to the contraction mechanism, structure, and electrophysiology of the left ventricle. Results: At the left ventricular mesoscale, we observed that weakly contracting myocardial units are transiently elongated by the contraction of adjacent, more strongly contracting units. These mesoscale interactions generate a ?tug-of-war? that pervades the left ventricle in healthy hearts and becomes particularly prominent following myocardial infarction. This behavior is macroscopically invisible as the contraction patterns of opposing units cancel each other out, but it nevertheless shapes the efficiency of mechanical performance. In the healthy heart, recruitment of more uniformly contracting units (i.e., reduction in tug-of-war) supports augmented contractility during acute stress. However, following myocardial infarction, excessive tug-of-war contributes to impaired contractile efficiency and performance. Computational modelling showed that the ventricular contraction mechanism, structure, and electrophysiology underpin this behavior in healthy hearts and exacerbate it in disease. Conclusion: Left ventricular systolic function is characterized by a myocardial tug-of-war at the mesoscale, which contributes to the heart's adaptability in health and its vulnerability in disease. These findings introduce a new concept for understanding left ventricular function and a novel analytical approach for investigating its failure.
Open AccessMyocardial Tug-of-War Is a Determinant of Left Ventricular Function and Failure
Background: Heart failure with reduced ejection fraction is a leading cause of death worldwide, characterized by impaired left ventricular systolic function. Contractile, structural, and electrophysiological changes underpin this impairment, but how these changes collectively determine ventricular function remains unclear. We hypothesize that their integrated action involves a complex mechanical interplay at the myocardial mesoscale level, intermediate between individual cardiomyocytes and the global left ventricle. Methods: We acquired high-resolution magnetic resonance images of healthy individuals and patients with myocardial infarction, and developed an analytical method to characterize in vivo contraction patterns in millimeter-sized myocardial units (i.e., at the mesoscale). Furthermore, we employed computational models to examine how mesoscale contraction patterns relate to the contraction mechanism, structure, and electrophysiology of the left ventricle. Results: At the left ventricular mesoscale, we observed that weakly contracting myocardial units are transiently elongated by the contraction of adjacent, more strongly contracting units. These mesoscale interactions generate a ?tug-of-war? that pervades the left ventricle in healthy hearts and becomes particularly prominent following myocardial infarction. This behavior is macroscopically invisible as the contraction patterns of opposing units cancel each other out, but it nevertheless shapes the efficiency of mechanical performance. In the healthy heart, recruitment of more uniformly contracting units (i.e., reduction in tug-of-war) supports augmented contractility during acute stress. However, following myocardial infarction, excessive tug-of-war contributes to impaired contractile efficiency and performance. Computational modelling showed that the ventricular contraction mechanism, structure, and electrophysiology underpin this behavior in healthy hearts and exacerbate it in disease. Conclusion: Left ventricular systolic function is characterized by a myocardial tug-of-war at the mesoscale, which contributes to the heart's adaptability in health and its vulnerability in disease. These findings introduce a new concept for understanding left ventricular function and a novel analytical approach for investigating its failure.
- Open Access
- 5 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Testosterone exacerbates neutrophilia and cardiac injury in myocardial infarction via actions in bone marrow
Men develop larger infarct sizes than women after a myocardial infarction (MI), but the mechanism underlying this sex difference is unknown. Here, we demonstrated that blood neutrophil counts post-MI were higher in male than female mice. Castration-induced testosterone deficiency reduced blood neutrophil counts to the level in females and increased survival post-MI. These effects were mimicked by Osterix-directed ablation of the androgen receptor in bone marrow (BM). Mechanistically, androgens downregulated the leukocyte retention factor CXCL12 in BM stromal cells. Post-hoc analysis of clinical trial data showed that neutrophilia was greater in men than women after reperfusion of first-time ST-elevation MI, and tocilizumab, an interleukin-6 receptor inhibitor, reduced blood neutrophil counts and infarct size to a greater extent in men than women. Our work reveals a previously unknown mechanism connecting testosterone with neutrophilia and MI injury via BM and identifies the importance of considering sex when developing anti-inflammatory strategies to treat MI.
- 5 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessTestosterone exacerbates neutrophilia and cardiac injury in myocardial infarction via actions in bone marrow
Men develop larger infarct sizes than women after a myocardial infarction (MI), but the mechanism underlying this sex difference is unknown. Here, we demonstrated that blood neutrophil counts post-MI were higher in male than female mice. Castration-induced testosterone deficiency reduced blood neutrophil counts to the level in females and increased survival post-MI. These effects were mimicked by Osterix-directed ablation of the androgen receptor in bone marrow (BM). Mechanistically, androgens downregulated the leukocyte retention factor CXCL12 in BM stromal cells. Post-hoc analysis of clinical trial data showed that neutrophilia was greater in men than women after reperfusion of first-time ST-elevation MI, and tocilizumab, an interleukin-6 receptor inhibitor, reduced blood neutrophil counts and infarct size to a greater extent in men than women. Our work reveals a previously unknown mechanism connecting testosterone with neutrophilia and MI injury via BM and identifies the importance of considering sex when developing anti-inflammatory strategies to treat MI.
- Open Access
- 15 September 2023
- Published by Elsevier in Resuscitation
- Vol. 193, 109970
Cardiovascular changes induced by targeted mild hypercapnia after out of hospital cardiac arrest. A sub-study of the TAME cardiac arrest trial
- 15 September 2023
- Published by Elsevier in Resuscitation
- Vol. 193, 109970
Open AccessCardiovascular changes induced by targeted mild hypercapnia after out of hospital cardiac arrest. A sub-study of the TAME cardiac arrest trial
- Open Access
- 1 January 2022
- Published by Elsevier in Molecular Immunology
- Vol. 141, 273-279
Complement ratios C3bc/C3 and sC5b-9/C5 do not increase the sensitivity of detecting acute complement activation systemically
- 1 January 2022
- Published by Elsevier in Molecular Immunology
- Vol. 141, 273-279
Open AccessComplement ratios C3bc/C3 and sC5b-9/C5 do not increase the sensitivity of detecting acute complement activation systemically
- 16 December 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 8 (3) , E11
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Geir Øystein Andersen; Correspondence: Comment on the noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic h
- 16 December 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 8 (3) , E11
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Geir Øystein Andersen; Correspondence: Comment on the noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic h
- 1 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (Supplement)
The role of IL-6 receptor trans-signalling in ischemia-reperfusion injury, infarct healing and future adverse events in patients with ST-Elevation Myocardial Infarction
Background: Inflammation has emerged as a new treatment target in patients with coronary artery disease, and inflammation seems to play an important role in the ischemia/reperfusion injury in ST-elevation myocardial infarction (STEMI). The pro-inflammatory cytokine interleukin-6 (IL-6) has been shown to be associated with myocardial injury and poor prognosis in patients with STEMI. Purpose: The aim of the study was to further elucidate possible associations between the IL-6 trans-signalling system and final infarct size, myocardial function, adverse remodelling, and future cardiovascular events in patients with STEMI. Methods: A total of 272 patients with first-time STEMI included in the POSTEMI study on ischaemic postconditioning, with symptom duration median) at all sampling points were significantly associated with increased infarct size and reduced left ventricular ejection fraction (LVEF) measured by CMR. Additionally, high levels of IL-6 (> median) at day 1 were associated with lower myocardial salvage, more presence of microvascular obstruction and larger increase in indexed LV end diastolic volume (LVEDVi). IL-6R measured during hospitalisation was significantly associated with change in LVEDVi, but did not associate with infarct size, LVEF or myocardial salvage. High levels of IL-6 (>75th percentile) at all sampling points were associated with an increased risk of having an adverse clinical event during the first year and with long-term all-cause mortality (Figure 2), whereas there was no association between IL-6R and adverse clinical events. Conclusion: Patients with high IL-6 levels during the acute phase of STEMI had larger infarct size, reduced myocardial salvage, reduced LV function and worse clinical outcome than patients with lower levels of IL-6. High levels of IL-6 measured after 4 months were associated with larger infarct size, reduced LVEF and increased all-cause mortality. IL-6R was significantly associated with increase in LVEDVi. The results add important information to the role of IL-6 in myocardial injury in acute STEMI and the IL-6 pathway as a potential treatment target. Funding Acknowledgement: Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Stein Erik Hagen Foundation for Clinical Heart Research, Oslo, Norway. Figure 1Figure 2
- 1 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (Supplement)
The role of IL-6 receptor trans-signalling in ischemia-reperfusion injury, infarct healing and future adverse events in patients with ST-Elevation Myocardial Infarction
Background: Inflammation has emerged as a new treatment target in patients with coronary artery disease, and inflammation seems to play an important role in the ischemia/reperfusion injury in ST-elevation myocardial infarction (STEMI). The pro-inflammatory cytokine interleukin-6 (IL-6) has been shown to be associated with myocardial injury and poor prognosis in patients with STEMI. Purpose: The aim of the study was to further elucidate possible associations between the IL-6 trans-signalling system and final infarct size, myocardial function, adverse remodelling, and future cardiovascular events in patients with STEMI. Methods: A total of 272 patients with first-time STEMI included in the POSTEMI study on ischaemic postconditioning, with symptom duration median) at all sampling points were significantly associated with increased infarct size and reduced left ventricular ejection fraction (LVEF) measured by CMR. Additionally, high levels of IL-6 (> median) at day 1 were associated with lower myocardial salvage, more presence of microvascular obstruction and larger increase in indexed LV end diastolic volume (LVEDVi). IL-6R measured during hospitalisation was significantly associated with change in LVEDVi, but did not associate with infarct size, LVEF or myocardial salvage. High levels of IL-6 (>75th percentile) at all sampling points were associated with an increased risk of having an adverse clinical event during the first year and with long-term all-cause mortality (Figure 2), whereas there was no association between IL-6R and adverse clinical events. Conclusion: Patients with high IL-6 levels during the acute phase of STEMI had larger infarct size, reduced myocardial salvage, reduced LV function and worse clinical outcome than patients with lower levels of IL-6. High levels of IL-6 measured after 4 months were associated with larger infarct size, reduced LVEF and increased all-cause mortality. IL-6R was significantly associated with increase in LVEDVi. The results add important information to the role of IL-6 in myocardial injury in acute STEMI and the IL-6 pathway as a potential treatment target. Funding Acknowledgement: Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Stein Erik Hagen Foundation for Clinical Heart Research, Oslo, Norway. Figure 1Figure 2
- Open Access
- 1 September 2021
- Published by Elsevier in Resuscitation
- Vol. 166, 129-136
Complement activation is associated with poor outcome after out-of-hospital cardiac arrest
- 1 September 2021
- Published by Elsevier in Resuscitation
- Vol. 166, 129-136
Open AccessComplement activation is associated with poor outcome after out-of-hospital cardiac arrest
- Open Access
- 1 May 2021
- Published by Elsevier in Resuscitation
- Vol. 162, 35-42
Outcome in refractory out-of-hospital cardiac arrest before and after implementation of an ECPR protocol
- 1 May 2021
- Published by Elsevier in Resuscitation
- Vol. 162, 35-42
Open AccessOutcome in refractory out-of-hospital cardiac arrest before and after implementation of an ECPR protocol
- Open Access
- 1 May 2021
- Published by Elsevier in Resuscitation
- Vol. 162, 372-380
Health-related quality of life after out-of-hospital cardiac arrest – a five-year follow-up study
- 1 May 2021
- Published by Elsevier in Resuscitation
- Vol. 162, 372-380
Open AccessHealth-related quality of life after out-of-hospital cardiac arrest – a five-year follow-up study